Future challenges in the elimination of bacterial meningitis (Q38011321)

26 August 2017

Future challenges in the elimination of bacterial meningitis (English)

1 reference

26 August 2017

1 reference

4

Keith P Klugman

1 reference

26 August 2017

2

Davide Serruto

1 reference

26 August 2017

Matthew J Bottomley

1

1 reference

PubMed ID

22607903

26 August 2017

Marco Aurélio Palazzi Sáfadi

series ordinal

3

1 reference

PubMed ID

22607903

26 August 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

30 Suppl 2

1 reference

26 August 2017

B78-86

1 reference

Bacterial meningitis in the United States, 1998-2007.

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Bacterial meningitis in the United States in 1995. Active Surveillance Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Epidemiology of bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Advances in the development of vaccines against Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Global epidemiology of meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Systematic review: neonatal meningitis in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Neonatal group B streptococcal disease: from pathogenesis to preventive strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Serogroup B meningococcal vaccines-an unfinished story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Rapid diagnosis of pneumococcal meningitis: implications for treatment and measuring disease burden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in Niger.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Global use of Haemophilus influenzae type b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Streptococcus pneumoniae pilus subunits protect mice against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Genome-based approaches to develop vaccines against bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Meningococcal disease and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Meningococcal protein antigens and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

New frontiers in meningococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Accelerating policy decisions to adopt haemophilus influenzae type B vaccine: a global, multivariable analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Progress in vaccination against Haemophilus influenzae type b in the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Haemophilus influenzae type b reemergence after combination immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

7 January 2021

Vaccine policy in India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

The Meningitis Vaccine Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

The future of pneumococcal disease prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

New approaches to the assessment of vaccine herd protection in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Risk of red queen dynamics in pneumococcal vaccine strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Mechanisms of meningococcal colonisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Bacteremia among children admitted to a rural hospital in Kenya.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Causes and outcome of young infant admissions to a Kenyan district hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected childre

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Group B Streptococcus: global incidence and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Identification of a universal Group B streptococcus vaccine by multiple genome screen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Neonatal Group B Streptococcal bacteraemia in India: ten years' experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Neonatal meningitis according to the microbiological diagnosis: a decade of experience in a tertiary center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

An update on vaccination against group B streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Epidemiologic surveillance and evaluation of meningitis hospital care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

A 2020 vision for vaccines against HIV, tuberculosis and malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Prospects for a vaccine against otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Clinical course, complications and sequelae of acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Haemophilus influenzae type a infection and its prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

CSF markers for diagnosis of bacterial meningitis in neurosurgical postoperative patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

Streptococcus suis, an important cause of adult bacterial meningitis in northern Vietnam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

[Risk factors for bacterial meningitis in the newborn]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

inferred from DOI database lookup

7 January 2021

based on heuristic

Myelomeningocele: a Brazilian University Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.099

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.12.099

1 reference

26 August 2017

1 reference

PubMed ID

22607903